Cathepsin B is secreted apically from *Xenopus* 2F3 cells and cleaves the epithelial sodium channel (ENaC) to increase its activity

Abdel A. Alli, John Z. Song, Otor Al-Khalili, Hui-Fang Bao, He-Ping Ma, Alia A. Alli, and Douglas C. Eaton

Department of Physiology, Emory University School of Medicine and the Center for Cell and Molecular Signaling, Atlanta Georgia

Corresponding author:
Abdel A. Alli, Ph.D.
Department of Physiology
Emory University School of Medicine
Atlanta, GA 30345
aalli@emory.edu

Running title: Cathepsin B cleaves ENaC

Capsule:

**Background:** Epithelial sodium channels (ENaC) are activated by proteolytic cleavage. Several proteases including furin and prostasin cleave ENaC.

**Results:** Cathepsin B also cleaves and activates ENaC. Cathepsin B cleaves ENaC alpha but not beta or gamma subunits.

**Conclusion:** Cathepsin B is a secreted protease so it may cleave ENaC at the cell surface.

**Significance:** Cathepsin B cleavage represents a novel ENaC regulatory mechanism.
ABSTRACT

The epithelial sodium channel (ENaC) plays an important role in regulating sodium balance, extracellular volume, and blood pressure. Evidence suggests the alpha and gamma subunits of ENaC are cleaved during assembly before they are inserted into the apical membranes of epithelial cells; and maximal activity of ENaC depends on cleavage of the extracellular loops of alpha and gamma subunits. Here, we report that *Xenopus* 2F3 cells apically express the cysteine protease Cathepsin B, as indicated by two-dimensional gel electrophoresis and mass spectrometry analysis. Recombinant GST ENaC alpha, beta, and gamma subunit fusion proteins were expressed in *E. coli* and then purified and recovered from bacterial inclusion bodies. *In vitro* cleavage studies revealed the full length ENaC alpha subunit fusion protein was cleaved by active cathepsin B, but not the full length beta or gamma subunit fusion proteins. Both single channel patch clamp studies and short circuit current experiments show ENaC activity decreases with the application of a cathepsin B inhibitor directly onto the apical side of 2F3 cells. We suggest a role for the proteolytic cleavage of ENaC by cathepsin B, and we suggest two possible mechanisms by which cathepsin B could regulate ENaC. Cathepsin B may cleave ENaC extracellularly after being secreted or intracellularly while ENaC is present in the golgi or in recycling endosomes.
INTRODUCTION

Epithelial sodium channels (ENaC) are expressed within the apical membranes of epithelial cells, primarily in the collecting tubules of the kidney, lung, and colon. ENaC plays an important role in the regulation of renal sodium transport and helps maintain total body water and salt homeostasis. Specific mutations in ENaC lead to inherited forms of hypertension (e.g. Liddle’s syndrome) and hypotension (e.g. pseudohypoaldosteronism type 1) (1-5).

ENaC functions most efficiently as a heteromultimeric protein complex formed from alpha, beta, and gamma subunits, but the alpha subunit alone may also form functional channels. Each of the three ENaC subunits consists of short intracellular NH2 and COOH domains, a large extracellular loop, and two transmembrane domains. Ion channels can be activated by selective ligands (6,7), chemical compounds (8), hormones (6,9), intrinsic signaling (6,10), and by proteolytic cleavage (8,11,12). Several reports suggest the gating of ENaC is regulated by cations (13), anions (14), sodium (15), protons (16), and proteases (17-26). Recent evidence has shown that ENaC is activated when cleaved by several different tryptic proteases including channel-activating protease 1/2 (27-29), neutrophil elastase (22), trypsin (30), furin (31,32), and prostasin (32-34). The cleavage of ENaC was found to occur mainly in the golgi apparatus before ENaC is inserted into the membrane. The ability of secreted proteases to cleave and activate ENaC has not been thoroughly investigated.

Various epithelial cells are known to secrete proteases. Cathepsin B is a lysosomal cysteine protease that is expressed in epithelial cells and tissues (35). The active enzyme is secreted upon lysosomal exocytosis or extracellular processing by surface activators (36). Cathepsin B is different from other cathepsins in that it functions as an endopeptidase at neutral pH and can be found outside of lysosomes including in the cytoplasm, the plasma membrane, and in the extracellular space. Cathepsin B contributes to various biological processes including inflammation, cancer metastasis, apoptosis, and differentiation (37-41).

Like other integral membrane proteins, ENaC is susceptible to proteolysis by secreted proteases in response to physiological and pathophysiological conditions. Here we demonstrate that the commonly used Xenopus 2F3 subclone of the A6 cell line in the study of the regulation of ENaC secretes the protease cathepsin B exclusively on the apical side. Our findings also show that this protease can cleave ENaC in vitro and activate ENaC in situ.

MATERIALS AND METHODS

Cell culture

2F3 cells were a kind gift of Dr. Dale Benos. The cells were seeded onto permeable polyester inserts and cultured in 50/50 Dulbecco’s MEM/Ham’s F-12 base media (Gibco, Grand Island, NY) at pH 7.4 and supplemented with 5% fetal bovine serum (Gibco), 1.5 µM aldosterone, 0.6% penicillin, 1% streptomycin (Irvine Scientific, Santa Ana, CA). Cells were maintained in a humidified incubator with 4% CO2 in air. Experiments were performed using cells between passages 98 and 106.

Two-dimensional gel electrophoresis

Apical and basolateral media was subject to a clean-up procedure using the ReadyPrep 2D cleanup kit (Bio-Rad) to concentrate the sample and to remove contaminants that could interfere with the IEF. Two-hundred micrograms of the purified protein sample prepared in 125 µL of rehydration/sample buffer (8 M urea, 2% CHAPS, 50 mM dithiothreitol (DTT), 0.2% (w/v) Bio-lyte 3/10 ampholytes, and bromophenol blue)
was applied to IPG strips (pH 4-7 ReadyStrip, 7 cm, Bio-Rad). The strips were allowed to rehydrate for 16 hrs at room temperature. The rehydrated IPG strips were transferred to an IEF focusing tray and electrode wicks were used as receptacles for non-amphoteric constituents. The IPG strips were covered with mineral oil and then focused using a Protean IEF cell (Bio-Rad) according to the following parameters (250 V, linear ramp, 20 minutes; 4,000 V, linear ramp, 2 hrs; 4,000 V rapid ramp, 10,000 V-hrs; 20 °C, 50 µA/strip). Focused IPG strips were transferred to an equilibration tray and incubated with 2.5 mL of equilibration buffer 1 (6 M urea, 2% SDS, 0.375 M Tris-HCl (pH 8.8), 20% glycerol, and 2% (w/v) DTT) for 10 minutes on an orbital shaker at room temperature. The IPG strips were then incubated with 2.5 mL of equilibration buffer 2 (6 M urea, 2% SDS, 0.375 M Tris-HCl (pH 8.8), 20 % glycerol, and with 2.5% (w/v) iodoacetamide) for 10 minutes on an orbital shaker at room temperature.

**Coomassie staining**

In order to visualize the separated proteins, 4-15% gradient IPG gels were fixed with Colloidal Coomassie fixing solution (45% methanol, 1% acetic acid, 54% ultra-pure H2O) for 1 hr and then stained with Colloidal Coomassie staining solution (170 g/L ammonium sulphate, 1 g/L Coomassie G250, 0.5% acetic acid, 34% methanol) for 8 hrs, and then destained in destaining solution (5% methanol, 95% ultra-pure H2O) for 8 hrs.

**MALDI-TOF mass spectrometry**

Selected protein spots were excised from Coomassie stained gels and then transferred to keratin-free tubes. The gel spots were subject to in-gel tryptic digestion followed by liquid extraction of the gel fragments. The peptides were extracted and concentrated under vacuum centrifugation. A nanoflow liquid chromatograph (Easy-nLC, Proxeon, Odense, Denmark) coupled to an electrospray ion trap mass spectrometer (LTQ, Thermo, San Jose, CA) was used for tandem mass spectrometry peptide sequencing experiments. Spectra were analyzed by searching with the publicly available search algorithm Mascot (http://www.matrixscience.com/cgi/search_form.pl?FORMVER=2&SEARCH=PMF) using the National Center for Biotechnology Information (NCBI) and SwissProt databases.

**SDS-PAGE and Immunoblot analysis**

2F3 cells were washed with 1XPBS and lysed with mammalian protein extraction reagent (MPER) (Thermo Scientific; Rockford, IL, USA) containing protease and phosphatase inhibitors (Thermo Scientific) followed by passing the lysate five times through a 23 gauge needle with a syringe before being incubated on ice for 1 hr. Protein concentration was determined using the BCA assay (Thermo Scientific) according to the manufactures instructions. Samples were prepared in Laemmli sample buffer (Bio-Rad, Hercules, CA) supplemented with 5% β-mercaptoethanol. One hundred micrograms of protein was loaded and resolved on 7.5 % Tris-HCl polyacrylamide precast gels using either the Criterion or Protean Western blotting system (Bio-Rad). The separated proteins were electrophoretically transferred to Hybond C-extra nitrocellulose membranes (GE Healthcare, Piscataway, NJ) and then blocked in 5% (w/v) dry milk in 1XTBS (Bio-Rad) for 1 hr at room temperature. Immunoblotting was performed by first incubating the blocked membranes with peroxidase conjugated anti-GST antibody (Sigma) or anti-cathepsin B antibody (Cell Signaling Technologies) at a 1:1000 dilution prepared in 5% BSA-1XTBS for 8 hrs at 4 °C. After a series of three 5 minute washes with 1XTBS, the membranes were incubated with HRP-conjugated goat anti-rabbit secondary antibody at a dilution of 1:3000
prepared in blocking solution. The immunoreactive bands were visualized using SuperSignal Dura Chemiluminescent Substrate kit (Pierce) according to the manufactures instructions. The membranes were exposed using the Kodak Gel Logic 2200 Imager and Molecular Imaging software system (Carestream Health, Rochester, NY, USA) and relative molecular masses of the immunoreactive bands were assessed using Precision Plus Protein Standards (Bio-Rad).

**Densitometric analysis**
Densitometry was conducted using ImageJ software (National Institutes of Health). Protein levels are presented as arbitrary units of a ratio between the band intensity for the protein of interest and the band intensity of actin.

**Recombinant protein production**
The entire coding sequence of each ENaC subunit was subcloned into the pGEX4T-2 expression vector. The constructs were transformed into competent *E. coli* cells and expression was induced with IPTG. The fusion proteins were purified and recovered from bacterial inclusion bodies as previously described by Alli and Gower (42,43).

**Electrophysiological transepithelial measurements**
The voltage and resistance across confluent monolayers were measured with an epithelial voltmeter (EVOM; World Precision Instrument, Sarasota, FL) and transepithelial amiloride-sensitive current was calculated per unit area according to Ohm's law before and after application of 10 μM cathepsin B inhibitor (CA-74) Calbiochem, San Diego, CA) or vehicle dimethyl sulfoxide (DMSO) (Sigma) at time points between 5 and 60 minutes. The cells were harvested for protein for biochemical studies as described above.

**Cell-attached single channel patch clamp studies**
Micropipettes were pulled (two-stage vertical puller; Tokyo, Japan) from filamentsed borosilicate glass capillaries (TW-150F, World Precision Instruments). The basolateral and apical membranes of 2F3 cells subcultured on Lucite rings were exposed to pipette solution (96 mM NaCl, 3.4 mM KCl, 0.8 mM MgCl₂, 0.8 mM CaCl₂, and 10 mM HEPES). The micropipettes were filled with the same patch solution and had a resistance between 5 and 10 MΩ. The product of the number of channels (N) and the single-channel open probability (Pₒ) was used to calculate ENaC activity within a patch. The number of current levels or the number of peaks detected in current amplitude histograms were used to estimate the total number of channels in a patch. The open probability of a single channel in a patch was calculated by dividing N Pₒ by the number of channels in a patch. Single channel currents from gigaohm seals were filtered at 100 Hz and recorded at 500 Hz using the Clampfit 10.1 software (Molecular Devices).

**In vitro cathepsin B cleavage assay**
Active Cathepsin B protease purified from human liver was purchased from Calbiochem (San Diego, Ca). Five micrograms of freshly prepared recombinant ENaC GST fusion proteins in elution buffer was incubated with 5 µg of Cathepsin B protease at 37 °C for 8 hrs. The reactions were terminated by adding sample buffer containing SDS. The samples were analyzed by SDS-PAGE and Coomassie staining.

**siRNA mediated knockdown of Cathepsin B**
siRNA targeting cathepsin B (sense, 5'-AGUCUAUGGCAGUGACAAAUU-3'; antisense, 5'-UUUGUCACGUCAGACUUU-3') was designed using the siDESIGN tool and purchased from Thermo Scientific. As a control, non-targeting siRNA was used (siGENOME non-targeting siRNA #2;
Cells were transfected with siRNA using Xfect transfection reagent (Clontech; Mountain View, CA) while following the manufacturer's instructions.

**Cell Surface Biotinylation**

Confluent cells grown on transwell permeable support were treated with drug or vehicle for 3 hrs in an incubator. The apical side of the inserts was washed twice with sterile ice cold PBS and then incubated for 30 minutes in ice cold borate buffer (85 mM NaCl, 4 mM KCl, 15 mM NaB4O7, pH 9.0) containing biotin (ThermoScientific) (0.5 mg/mL). The cells were then washed with lysine solution (18.3 g/L of complete growth medium) and then incubated for 15 minutes in the same solution. The cells were washed with sterile ice cold PBS and lysed in MPER containing protease and phosphatase inhibitors. The lysate was incubated with prewashed avidin beads and incubated for 6 hrs at 4°C. The complex was washed three times with sterile PBS and proteins were eluted by boiling for 10 minutes at 100°C in SDS sample buffer. Thirty microliters of the prepared sample was loaded and resolved on 7.5% Tris-HCl polyacrylamide gels and subject to SDS-PAGE and immunoblotting as mentioned above, but with anti-ENaC alpha antibody (44) at a dilution of 1:1000.

**Statistical Analysis**

The values obtained from experiments performed in triplicates (n=3) are presented as mean ± SEM. Statistical significance was determined by using the Student's t-test at P < 0.05.

**RESULTS**

*Cathepsin B is found in the apical but not basolateral medium from confluent Xenopus 2F3 cells*

The 2F3 cell line remains an excellent model system to study the regulation of ENaC using biochemical and electrophysiological approaches. ENaC is known to be activated by various proteases. In order to determine if 2F3 cells secrete any proteases for which ENaC could be a substrate, media from the apical and basolateral sides of these cells were concentrated and then subject to two-dimensional gel electrophoresis. Since the samples were processed extensively in order to remove contaminants that could potentially minimize resolution and cause vertical and horizontal streaking, spot profiles from the apical and basolateral samples could be analyzed and the protein spots could be identified by mass spectrometry. The proteins were separated by their isoelectric point in the horizontal direction and then by their molecular weight in the vertical direction. Several spots corresponding to proteins unique to either the apical or basolateral sides were excised and subject to mass spectrometry sequencing for protein identification. Figure 1 shows one such protein spot that was found on the apical side, but not the basolateral side. Mass spectrometry analysis of this protein spot revealed multiple signature peptides corresponding to cathepsin B (Fig 1C).

*ENaC is cleaved in vitro in the presence of active cathepsin B*

In order to determine whether each of the three structurally similar but distinct ENaC subunits could be substrates of cathepsin B, we first subcloned the full *Xenopus* coding sequence of each subunit into a bacterial expression vector comprising a GST tag. Recombinant fusion proteins can be valuable resources in many different applications because they can serve as a renewable source of purified protein and they can be obtained in large quantities. However, expression of foreign proteins in bacterial systems, and particularly those proteins with hydrophobic domains often pose problems because they tend to
aggregate in bacterial inclusion bodies. Each of the ENaC subunits contains two transmembrane domains and aggregated in inclusion bodies. Using a system previously described by Alli et al., we expressed each ENaC subunit as a GST fusion protein and then purified them from bacterial inclusion bodies. The expression of foreign proteins in a bacterial system also results in the protein being prematurely cleaved by host proteases and the purification of those proteins often results in copurification of host proteins. Therefore, we excised protein bands that corresponded to each of the three ENaC subunits from Coomassie stained gels and confirmed the identity and coverage of the proteins by mass spectrometry. Mascot reports of the mass spectral data revealed multiple large signature peptides corresponding to ENaC gamma (Fig. 2C), ENaC beta (Fig. 3C), and ENaC alpha (Fig. 4C). Of the two proteins bands excised from Coomassie stained gels after SDS-PAGE analysis of recombinant GST ENaC gamma (Fig. 2B), the lower molecular weight band represents ENaC gamma without the GST moiety while the higher molecular weight band represents ENaC gamma with the GST moiety (Fig. 2C). The mass spectrometry sequence coverage did not reveal any mutations or sequence coverage for the GST moiety of any of the ENaC subunit fusion proteins. The fusion proteins were used to perform in vitro cathepsin B cleavage experiments. The GST ENaC gamma fusion protein was subject to treatment with or without active cathepsin B protease. Coomassie stained gels and western blot analysis demonstrated a stained and immunoreactive band, respectively, of 100 kDa for ENaC beta fusion protein (Fig. 3). Also, further analysis revealed the GST ENaC beta subunit fusion was not cleaved by cathepsin B. Coomassie stained gels and western blot analysis demonstrated a stained and immunoreactive band, respectively, of 100 kDa for ENaC alpha fusion protein (Fig. 4). Unlike for recombinant GST ENaC gamma and GST ENaC beta fusion proteins, lower molecular bands were present when GST ENaC alpha fusion was exposed to cathepsin B (Fig. 4) suggesting cathepsin B cleavage of alpha.

The extracellular loop of ENaC alpha contains putative cathepsin B cleavage sites

The bioinformatics tool 'PEPS' (Prediction of Endopeptidase Substrates) was used to predict putative cathepsin B cleavage sites within the entire coding sequence of Xenopus ENaC subunits. PEPS overcomes limitations of other bioinformatics tools and has been found to offer reliable endopeptidase substrate predictions (45). The sequence of Homo sapiens cathepsin B that was used to perform the in vitro cathepsin B cleavage assays was compared to that of Xenopus laevis and found to be identical, as shown in Fig. 5A. At least one putative cathepsin B cleavage site lies within the extracellular loop of ENaC alpha (Fig. 5B). However, the beta and gamma subunits of ENaC lack putative cathepsin B cleavage sites.

Inhibition and siRNA mediated knockdown of cathepsin B decreases amiloride-sensitive transepithelial current in 2F3 cells

Amiloride-sensitive epithelial Na+ channels (ENaC) are responsible for transepithelial sodium transport. It is possible to correlate changes in ENaC activity at the apical membrane with changes in transepithelial current measured by an electrode voltage ohmmeter (EVOM) because it measures net transepithelial current. The correlation between changes in
transepithelial current and ENaC activity (based on EVOM measurements) are supported because an increase in transepithelial current can be attenuated with the addition of amiloride. As shown in figure 6A, application of a selective cathepsin B inhibitor significantly decreased ENaC activity in a dose and time dependent manner. The resistance measured before and after application of the inhibitor did not decrease, but instead slightly increased after application of the inhibitor (consistent with a decrease in apical ENaC conductance). The effect of the cathepsin B inhibitor on transepithelial current was corroborated by siRNA mediated knockdown of cathepsin B. A statistically significant decrease in transepithelial current was observed 48 hrs after transient transfection of siRNA targeting cathepsin B when compared to transfection of nontargeting siRNA in Xenopus 2F3 cells (Fig. 6B). Western blot analysis showed cathepsin B decreased at the protein level after siRNA transfection (Fig. 6C).

**Inhibition of cathepsin B decreases the number of active alpha ENaC in 2F3 cells**

In order to determine if inhibiting cathepsin B affects the open probability or the number of active channels in the apical membrane, or both, we performed single channel patch clamp studies. Figure 7 shows representative traces of eight patches with active ENaC channels, in which 2F3 cells were pretreated with vehicle or the cathepsin B inhibitor for 1 hour before acquiring a seal. The cathepsin B inhibitor significantly decreased the number of active channels at the membrane; however, the open probability of the remaining channels was unchanged from that prior to treatment. In order to further confirm cathepsin B affects the density of ENaC at the membrane, cell surface biotinylation studies were performed. As shown in Fig. 7C-D, representative Western blots show a statistically significant decrease in the density of alpha ENaC both in the cell lysate and at the membrane after treatment with the cathepsin B inhibitor.

**DISCUSSION**

Accumulating evidence suggests cleavage of the extracellular loop of alpha and gamma ENaC subunits by several tryptic proteases enhances the activity of the channel. This cleavage is thought to occur principally during channel assembly within the trans-golgi network (TGN) before ENaC is inserted into the apical membrane. It has been shown that there are at least two cleavage sites within the extracellular loop of the alpha and gamma subunits of mammalian ENaC. Besides there being other cleavage sites by other proteases than those that have been previously reported, ENaC may be cleaved at different points as it trafficks to the apical membrane. It is also possible that a population of uncleaved or partially cleaved ENaC at the membrane may be subject to further cleavage or a population of ENaC may be cleaved while being recycled. ENaC can be internalized through a clathrin dependent pathway and is subsequently localized to early endosomes. A population of the channels is targeted for lysosomal degradation while another population is deubiquitinated to allow recycling.

Cathepsin B is post-translationally processed in the rough endoplasmic reticulum, Golgi, endosomal, and lysosomal compartments (Fig. 8). Cathepsin B is also secreted into the extracellular space of various tumor epithelial cells(46,47). Taking this into consideration, along with our findings that cathepsin B is secreted on the apical side of 2F3 cells, we considered several possibilities: cathepsin B cleaving ENaC within the golgi during ENaC assembly, extracellular cleavage while ENaC is in the apical membrane, or cleavage within endosomes while ENaC is being recycled (Fig. 8).
We used a non-permeable inhibitor of cathepsin B in our patch clamp studies to investigate the role of cathepsin B secreted into the extracellular space. Because there is secreted cathepsin B on the apical side of our 2F3 cells, we predicted application of the inhibitor would not have an immediate effect since ENaC would already be cleaved. Therefore, prior to patching we pretreated our cells for at least one hour with the non-permeable form of the cathepsin B inhibitor in order to allow for a new population of uncleaved or partially cleaved ENaC to insert into the membrane. Both single-channel patch clamp studies and cell surface biotinylation studies suggest cathepsin B affects the density of ENaC at the membrane. In other experiments, when we applied active cathepsin B protease directly onto transporting 2F3 cells we did not observe a significant effect. This is likely because a majority, if not all, of the functional ENaC channels were already cleaved to produce maximal activity.

Our studies are consistent with those of others in that the alpha subunit of ENaC is subject to proteolytic cleavage. Cathepsin B appears to be a highly conserved protease, as suggested by multiple sequence alignments of at least twelve different organisms. Because it could be obtained in an active and purified form, human cathepsin B from human liver was used to determine if recombinant full length Xenopus ENaC alpha, beta, and gamma subunit fusion proteins could be cleaved by cathepsin B in vitro. We choose to perform our in vitro proteolytic cleavage experiments at optimal conditions to achieve maximum protease activity while minimizing potential degradation and nonspecific proteolytic activity. Therefore, our studies involved digesting each of the three recombinant GST ENaC subunit fusion proteins with or without cathepsin B at 37 °C for 8 hrs.

2F3 cells are a clone of the A6 cell line, and both cell lines are excellent models that are commonly utilized in electrophysiology to investigate the regulation of ENaC. Our findings of cathepsin B being secreted on the apical side of 2F3 cells are novel, because previous reports of cathepsin B being secreted by certain epithelial cells were limited to cancer cells. Cathepsin B can be released in the cytosol and has been found to contribute to various cellular processes including caspase activation (48,49) and arachidonic acid release (46). Foghsgaard et al showed cathepsin B regulates TNF induced AA release by cleaving cPLA2 (46). Since Wei et al has already shown arachidonic acid decreases ENaC activity (50), we investigated if Cathepsin B could differentially regulate ENaC when it is expressed in the cytoplasm or when it is expressed in the extracellular space after being secreted.

Another possible mechanism by which Cathepsin B could increase ENaC activity is through indirect proteolytic processing of other proteins, which could subsequently activate ENaC. Others have shown cathepsin B is involved in the transcriptional and post-translational processing of various proteinases. For example, cathepsin B is also a candidate for the regulation of TNF-α vesicle trafficking through the regulation of SNARE components (51). Since cathepsin B is such a versatile protease, future studies may look to investigate if proteins known to regulate the insertion, gating, recycling, or degradation of ENaC are also substrates for cathepsin B.

We screened the entire coding sequence of each Xenopus ENaC subunit using the PEPS algorithm in order to identify putative cathepsin B cleavage sites. The analysis revealed at least one site that might be recognized and cleaved by cathepsin B and that is within the extracellular loop domain of Xenopus ENaC.
alpha, but is not present in the extracellular loop of either Xenopus ENaC beta or gamma. This finding is consistent with our hypothesis that the extracellular loop of at least one ENaC subunit is cleaved after cathepsin B is secreted into the extracellular space. However, despite the algorithm identifying a putative cleavage site, the consensus sequence for cathepsin B remains ambiguous and substrate prediction algorithms are often not definitive. In fact, we observed multiple bands after digesting our purified ENaC alpha recombinant protein with active cathepsin B, which suggests that there could be multiple cathepsin B cleavage sites. Our initial attempt to confirm the cathepsin B consensus sequence using mass spectrometry was unsuccessful because we could not generate enough protein from the bands excised from Coomassie stained gels after digesting recombinant Xenopus ENaC protein with active cathepsin B. Confirming that cathepsin B cleaves ENaC alpha at the site predicted by PEPS and identifying the exact amino residues around the cleavage site will require extensive studies since there could be multiple cleavage sites. Our future plans are to mutate the putative cathepsin B cleavage site by site-directed mutagenesis, produce recombinant Xenopus ENaC alpha protein, and perform in vitro cathepsin B assay studies.

ACKNOWLEDGEMENTS
This research was supported by National Institutes of Health grants F32 DK093255-01 (to A.A.A), T32 DK007771 (to C.A.P), 5R01 DK067110 (to H.-P.M.), and R37 DK037963 (to D.C.E). We thank B. J. Duke for concentrating the media and for maintaining 2F3 cells in culture.
Reference List

1. Bertog, M., Cuffe, J. E., Pradervand, S., Hummler, E., Hartner, A., Porst, M., Hilgers, K. F., Rossier, B. C., and Korbmacher, C. (2008) J. Physiol 586, 459-475

2. Lu, C., Pribanic, S., Debonneville, A., Jiang, C., and Rotin, D. (2007) Traffic 8, 1246-1264

3. Konstas, A. A., Mavrelos, D., and Korbmacher, C. (2000) Pflugers Arch. 441, 341-350

4. Prince, L. S. and Welsh, M. J. (1999) Am. J. Physiol 276, C1346-C1351

5. Schild, L. (1996) Nephrologie 17, 395-400

6. Krusek, J., Dittert, I., Hendrych, T., Hnik, P., Horak, M., Petrovic, M., Sedlacek, M., Susanka, K., Svobodova, L., Tousova, K., Ujec, E., Vlachova, V., Vylicky, L., Vyskocil, F., and Vylicky, L., Jr. (2004) Physiol Res. 53 Suppl 1, S103-S113

7. Zimmermann, I. and Dutzler, R. (2011) PLoS. Biol. 9, e1001101

8. Lester, H. A. (1995) Harvey Lect. 91, 79-98

9. Furukawa, T. and Kurokawa, J. (2007) Pharmacol. Ther. 115, 106-115

10. Haddock, R. E. and Hill, C. E. (2002) J. Physiol 545, 615-627

11. Clark, E. B., Jovov, B., Rooj, A. K., Fuller, C. M., and Benos, D. J. (2010) J. Biol. Chem. 285, 27130-27143

12. Grant, A., Amadesi, S., and Bunnett, N. W. (2007) Protease-Activated Receptors: Mechanisms by Which Proteases Sensitize TRPV Channels to Induce Neurogenic Inflammation and Pain. In Liedtke WB and , H. S., editors. TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades, CRC Press, Inc, Boca Raton

13. Palmer, L. G. and Andersen, O. S. (1989) Biophys. J. 55, 779-787

14. Collier, D. M. and Snyder, P. M. (2009) J. Biol. Chem. 284, 29320-29325

15. Knight, K. K., Wentzlaff, D. M., and Snyder, P. M. (2008) J. Biol. Chem. 283, 27477-27482

16. Collier, D. M. and Snyder, P. M. (2009) J. Biol. Chem. 284, 792-798

17. Adebamiro, A., Cheng, Y., Johnson, J. P., and Bridges, R. J. (2005) J. Gen. Physiol 126, 339-352

18. Carattino, M. D., Hughey, R. P., and Kleyman, T. R. (2008) J. Biol. Chem. 283, 25290-25295

19. Chraibi, A., Vallet, V., Firsov, D., Hess, S. K., and Horisberger, J. D. (1998) J. Gen. Physiol 111, 127-138
20. Diakov, A., Bera, K., Mokrushina, M., Krueger, B., and Korbmacher, C. (2008) *J. Physiol* **586**, 4587-4608

21. Garcia-Caballero, A., Dang, Y., He, H., and Stutts, M. J. (2008) *J. Gen. Physiol* **132**, 521-535

22. Harris, M., Garcia-Caballero, A., Stutts, M. J., Firsov, D., and Rossier, B. C. (2008) *J. Biol. Chem.* **283**, 7455-7463

23. Hughey, R. P., Bruns, J. B., Kinlough, C. L., Harkleroad, K. L., Tong, Q., Carattino, M. D., Johnson, J. P., Stockand, J. D., and Kleyman, T. R. (2004) *J. Biol. Chem.* **279**, 18111-18114

24. Hughey, R. P., Carattino, M. D., and Kleyman, T. R. (2007) *Curr. Opin. Nephrol. Hypertens.* **16**, 444-450

25. Korbmacher, C. (2009) *J. Med. Invest* **56 Suppl**, 306-307

26. Vuagniaux, G., Vallet, V., Jaeger, N. F., Pfister, C., Bens, M., Farman, N., Courtois-Coutry, N., Vandewalle, A., Rossier, B. C., and Hummler, E. (2000) *J. Am. Soc. Nephrol.* **11**, 828-834

27. Garcia-Caballero, A., Dang, Y., He, H., and Stutts, M. J. (2008) *J. Gen. Physiol* **132**, 521-535

28. Planes, C., Randrianarison, N. H., Charles, R. P., Frateschi, S., Cluzeaud, F., Vuagniaux, G., Soler, P., Clerici, C., Rossier, B. C., and Hummler, E. (2010) *EMBO Mol. Med.* **2**, 26-37

29. Vallet, V., Pfister, C., Loffing, J., and Rossier, B. C. (2002) *J. Am. Soc. Nephrol.* **13**, 588-594

30. Nesterov, V., Dahlmann, A., Bertog, M., and Korbmacher, C. (2008) *Am. J. Physiol Renal Physiol* **295**, F1052-F1062

31. Harris, M., Garcia-Caballero, A., Stutts, M. J., Firsov, D., and Rossier, B. C. (2008) *J. Biol. Chem.* **283**, 7455-7463

32. Bruns, J. B., Carattino, M. D., Sheng, S., Maarouf, A. B., Weisz, O. A., Pilewski, J. M., Hughey, R. P., and Kleyman, T. R. (2007) *J. Biol. Chem.* **282**, 6153-6160

33. Wakida, N., Kitamura, K., Tuyen, D. G., Maekawa, A., Miyoshi, T., Adachi, M., Shiraishi, N., Ko, T., Ha, V., Nonoguchi, H., and Tomita, K. (2006) *Kidney Int.* **70**, 1432-1438

34. Adachi, M., Kitamura, K., Miyoshi, T., Narikiyo, T., Iwashita, K., Shiraishi, N., Nonoguchi, H., and Tomita, K. (2001) *J. Am. Soc. Nephrol.* **12**, 1114-1121

35. Mort, J. S. and Buttle, D. J. (1997) *Int. J. Biochem. Cell Biol.* **29**, 715-720

36. Podgorski, I. and Sloane, B. F. (2003) *Biochem. Soc. Symp.* **70**, 263-276

37. Eykelbosh, A. J. and Van Der Kraak, G. (2010) *Comp Biochem. Physiol A Mol. Integr. Physiol* **156**, 218-223

38. Foghsgaard, L., Wissing, D., Mauch, D., Lademann, U., Bastholm, L., Boes, M., Elling, F., Leist, M., and Jaattela, M. (2001) *J. Cell Biol.* **153**, 999-1010
39. Guenette, R. S., Mooibroek, M., Wong, K., Wong, P., and Tenniswood, M. (1994) *Eur. J. Biochem.* **226**, 311-321

40. Jane, D. T., Morvay, L., Dasilva, L., Cavallo-Medved, D., Sloane, B. F., and Dufresne, M. J. (2006) *Biol. Chem.* **387**, 223-234

41. Martel-Pelletier, J., Cloutier, J. M., and Pelletier, J. P. (1990) *J. Orthop. Res.* **8**, 336-344

42. Alli, A. A. and Gower, W. R., Jr. (2010) *J. Cell Biochem*. **110**, 985-994

43. Alli, A. A. and Gower, W. R., Jr. (2009) *Am. J. Physiol Cell Physiol* **297**, C1157-C1167

44. Alli, A.A., Bao, H.F., Alli, A.A., Aldrugh, Y., Song, J.Z., Ma H.P., Yu L., Al-Khalili, O. and Eaton, D.C (2012) Phosphatidylinositol phosphate-dependent regulation of Xenopus ENaC by MARCKS protein. *Am. J. Physiol Renal Physiol, in press.*

45. Lohmuller, T., Wenzler, D., Hagemann, S., Kiess, W., Peters, C., Dandekar, T., and Reinheckel, T. (2003) *Biol. Chem.* **384**, 899-909

46. Foghsgaard, L., Lademann, U., Wissing, D., Poulsen, B., and Jaattela, M. (2002) *J. Biol. Chem.* **277**, 39499-39506

47. Mort, J. S., Recklies, A. D., and Poole, A. R. (1985) *Prog. Clin. Biol. Res.* **180**, 243-245

48. Joy, B., Sivadasan, R., Abraham, T. E., John, M., Sobhan, P. K., Seervi, M., and T R S (2010) *Mol. Carcinog.* **49**, 324-336

49. Guicciardi, M. E., Deussing, J., Miyoshi, H., Bronk, S. F., Svingen, P. A., Peters, C., Kaufmann, S. H., and Gores, G. J. (2000) *J. Clin. Invest* **106**, 1127-1137

50. Wei, Y., Lin, D. H., Kemp, R., Yaddanapudi, G. S., Nasjletti, A., Falck, J. R., and Wang, W. H. (2004) *J. Gen. Physiol* **124**, 719-727

51. Ha, S. D., Martins, A., Khazaie, K., Han, J., Chan, B. M., and Kim, S. O. (2008) *J. Immunol.* **181**, 690-697
Figure Legends

Figure 1. Two-dimensional gel electrophoresis analysis of proteins located on the apical and basolateral side of 2F3 cells. Coomassie stained gel of proteins from media collected and concentrated from the apical side (A) or basolateral side (B) of Xenopus 2F3 cells that were subcultured on permeable supports and allowed to form tight junctions and generate a measurable transepithelial resistance and voltage. Some proteins were found to be exclusively on the apical or basolateral side. The protein spot in (A) labeled with an arrow was excised and identified as cathepsin B after mass spectrometry protein sequencing. C: Densitometric analysis of the protein spot indicated by an arrow in (A). D: Representative Western blot of cathepsin B expression in the cell lysate and in the media collected and concentrated from the apical and basolateral side of Xenopus 2F3 cells.

Figure 2. Characterization and proteolytic analysis of full length ENaC gamma subunit. A: Coomassie stained gel showing the expression of the entire gamma subunit of ENaC as a GST fusion protein (GST-ENaC gamma) after IPTG induction. B: Coomassie stained gel showing the double band corresponding to GST-ENaC gamma or ENaC gamma after batch purification. C: MASCOT mass spectrometry peptide sequence coverage of several signature peptides corresponding to Xenopus ENaC gamma subunit. The shaded residues represent oxidation of methionine residues or alkylation of cysteine residues. D: Western blot analysis of GST-ENaC using a peroxidase conjugated antibody against GST to detect a 100 kDa immunoreactive band corresponding to GST-ENaC gamma. E: Coomassie stained gel indicating GST-ENaC gamma is not cleaved by cathepsin B in vitro.

Figure 3. Characterization and proteolytic analysis of full length ENaC beta subunit. A: Coomassie stained gel showing the expression of the entire beta subunit of ENaC as a GST fusion protein (GST-ENaC beta) after IPTG induction. B: Coomassie stained gel showing the double band corresponding to GST-ENaC beta after batch purification. C: MASCOT mass spectrometry peptide sequence coverage of several signature peptides corresponding to Xenopus ENaC beta subunit. The shaded residues represent oxidation of methionine residues or alkylation of cysteine residues. D: Western blot analysis of GST-ENaC using a peroxidase conjugated antibody against GST to detect a 100 kDa immunoreactive band corresponding to GST-ENaC beta. E: Coomassie stained gel indicating GST-ENaC beta is not cleaved by cathepsin B in vitro.

Figure 4. Characterization and proteolytic analysis of full length ENaC alpha subunit. A: Coomassie stained gel showing the expression of the entire alpha subunit of ENaC as a GST fusion protein (GST-ENaC alpha) after IPTG induction. B: Coomassie stained gel showing a band corresponding to GST-ENaC alpha after batch purification. C: MASCOT mass spectrometry peptide sequence coverage of several signature peptides corresponding to Xenopus ENaC alpha subunit. The shaded residues represent oxidation of methionine residues or alkylation of cysteine residues. D: Western blot analysis of GST-ENaC using a peroxidase
conjugated antibody against GST to detect a 100 kDa immunoreactive band corresponding to GST-ENaC alpha. E: Coomassie stained gel indicating GST-ENaC alpha is cleaved by cathepsin B in vitro.

Figure 5. Sequence analysis of cathepsin B and ENaC. A: Multiple sequence alignment of Homo sapiens and Xenopus laevis cathepsin B. The amino acid sequence of cathepsin B is highly conserved between Homo sapiens and Xenopus laevis, as it is for several other species. B: Predicted cleavage site of cathepsin B in the extracellular loop of Xenopus ENaC alpha subunit. Based on known cleavage sites of other substrates of cathepsin B, the amino acid region underlined and in bold italics is the predicted cathepsin B cleavage site within the extracellular loop of the alpha subunit of ENaC.

Figure 6. Measurements of amiloride-sensitive transepithelial current in 2F3 cells. A: Transepithelial sodium current decreased with time after treating Xenopus 2F3 cells with 10 µM cathepsin B inhibitor. B: Transepithelial sodium current decreased after siRNA mediated knockdown of cathepsin B in Xenopus 2F3 cells. Values are presented as means ± SE, n = 3 for each data point. *P < 0.05. C: Representative Western blot showing a decrease in Cathepsin B at the protein level after siRNA mediated knockdown as presented in (B).

Figure 7. Single channel recording from Xenopus 2F3 cells showing an effect on ENaC activity after application of a cathepsin B inhibitor. A: Representative traces of Xenopus 2F3 cells pretreated with vehicle (DMSO) or cathepsin B inhibitor (CA-074) for 1 hr before acquiring a patch. B: Results of eight independent patch-clamp studies showing the cathepsin B inhibitor significantly decreased the number of active channels in a patch of Xenopus 2F3 cells. *P < 0.001. Empty patches were included in the calculation of N, but the inhibitor did not affect Po. C: Representative Western blot of three independent experiments showing a decrease in ENaC alpha protein in the cell lysate and at the membrane after treating Xenopus 2F3 cells with the cathepsin B inhibitor. WCL represents whole cell lysate and MBR represents membrane fractions. D: Densitometric analysis of immunoreactive bands in (C) showing a statistically significant decrease in ENaC alpha protein in either the whole cell lysate or membrane fractions after treatment with the Cathepsin B inhibitor relative to treatment with the vehicle (MOCK). n=3, *P < 0.05.

Figure 8. Proposed model depicting the cathepsin B cleavage dependent activation of ENaC. The cysteine protease cathepsin B is synthesized as a latent preproenzyme and posttranslationally processed in the rough endoplasmic reticulum, golgi, endosomal, and lysosomal compartments. Cathepsin B is secreted or found in the cytoplasm of certain epithelial cells. Unlike other cysteine proteases, cathepsin B exhibits both endopeptidase and exopeptidase activities. Cathepsin B is shown to potentially cleave the extracellular loop of the alpha subunit of ENaC either within the golgi, extracellularly, or within endosomes.
Fig. 1

A. APICAL SIDE
B. BASOLATERAL SIDE

SDS-PAGE (kDa)

MARKER PLUG

IEF (pI)

Arbitrary Units (spot/background)

C. Apical

D. WB: Cathepsin B
Fig. 2

**Western blot:**

- **A**: Coomassie stain after IPTG induction
- **B**: Coomassie stain after batch purification
- **C**: Coomassie stain after cathepsin cleavage
- **D**: GST-ENaC Gamma
- **E**: GST

**MASCOT results from MS/MS**

| Peptide Sequence | MASCOT Results |
|------------------|----------------|
| MSNSGKKTQ KLKKNLPTVG PQAPTLYELM QWYCLNTNTH | |
| GCRIRVVKSG RLRRIWIVLTLIIVALIFW QCALLLMYY | |
| SVSASITVTF QKLVYPAVTCNLNPYSYSKIKDRLATLEK | |
| TTNQLKLYGTFEPLIRSRKRDLDVNDENS TEDIFLKQIP | |
| LFRLIESIKGNQLVVSNDKTKKRTQISGKVIRQDAGSVQDS | |
| DNQVFKLCDDANNSSDCGTFGVNIAQEWYRLYNNNI | |
| LAKISMEDKI AMGYKADELTVCPLLGLSCDARNFTLFHH | |
| PLYGNCYTFN SAEGRNLVSLSTGGAEYGKLVLYIDEDEY | |
| NPYLSKAGAAKILLVHDQDEYPFIEDLGTEL ETGTETSIGM | |
| QLTESTKLDSPSYDCTIDGSDISVENLYNKYTQLICLNS | |
| CFQREMVRSCGCAHYDQPLPNGAKYCNYEYPNWYCYVKE | |
| LYKQFVQOEELGQGSTRESSEFKETLIRS LAKWPSLNSLE | |
| EWLRLVLSWELGEKLKNKLTKNLDGNLNFQYLDNRSSIDS | |
| ESYTNYIVTLLSFNGGQQLGWLMSCSMVCGLEIVEVFIDS | |
| FWVILRQKWHKLKNWWKNRKENEIEIEIPDITVPAMAGHNN | |
| PLCVDHPICLGEDDPPTFHSALQLPQAQDRCRVPRTPPPKY | |
| NTLRIQSAFHLTETDSDEDEVRF | |

**Coomassie Stain**

- **kDa**: 250, 150, 100, 75, 50, 37

**Western blot: anti-GST**

- **kDa**: 250, 150, 100, 75, 50, 37
**Fig. 3**

**A**

**B**

**C**

**D**

**E**

**Coomassie stain after IPTG induction**

**Coomassie stain after batch purification**

**Western blot: anti-GST**

**Coomassie stain after cathepsin cleavage**

**MASCOT results from MS/MS**

**D**

**E**

**MASCOT results from MS/MS**

**Western blot: anti-GST**

**Coomassie stain after cathepsin cleavage**

**MIHGKMKRLK RYGTRALHRI QKGPGYTYKE LLVWFQYDNTN THGPKRIIKE GPKKRVMWFIL TLVLFAGLVF WQWGVLILTY LSYGVVSVLS IGGKTFIEPA VTL3NANPFR YSRVFKLLKE LDELVATLD RIQQSQNQOG NTFTTHNNQTR QNVTLDPAW NHIPLVVIDE TDPRNPIIHNI IFDNNAVYSK NSSIRNNSSED QTSYSQRYKV AMKLE7TNNT QCQYRNFSTG VQALREWYLL QLSSIFSNVP LSGRIDMGFK AEDLILTQLF GQPOP3YRNF THIYDADYGN CYIFNWQGQEG ENTMSSANPG ADFGLKLVLD IEOQGEYLPFL QTTAAAARLIL HQQRSFPFVK DLGIYAMPQT ETSIAVLVDQ LEHMEAPYSS CTVNGSDIPV QNLYAEFNSS YSIQSCLSSC YQEMVKTCK QAHYQYPLPN GSEY3TNKH PDWVFQYYSYL RDSVAILABLENQ ISL6QQPOE ND THYKMVISA DWPSAGAEDW IFHVLSYKD SSHNITVNRN GIVRLNIFYQ EFINYRSISES EATNWVWLLS NLGGQFGFWM GGSVLCIIEF GEIIIDCVWI TILKFLAWSR NRRQRRKRPQ YSDPPTVSE LVEAHTNPGF QHDDGDHVFP DIPGTPPPNY DLSR7NTAEP VSSDEEN
**Fig. 4**

**A**
- Coomassie stain after IPTG induction
- Coomassie stain after batch purification

**B**
- Western blot: anti-GST

**C**
- MASCOT results from MS/MS

**D**
- GST-ENaC Alpha
- GST

**E**
- Cathepsin b
  - Western blot: anti-GST after cathepsin cleavage
A

Cathepsin B [Homo sapiens]  MWQLWASLOCLLVLANARSRPSFHPLSDELVNYVNRNNTTWQAGHNFYNV
Cathepsin B [Xenopus laevis]  MWHLVVALCFLASIASSRHLPYFAFLSHMDVNYINKVNTTWKAGHNFANA
Cathepsin B [Homo sapiens]  DMSYLKRLOGTFGKGKPFQVMFTEDKLKPASFDAREQWPQCPTIKEIR
Cathepsin B [Xenopus laevis]  DLHYVKRLOGTLLKPGQ7KRFGFA0GLEDPDSDSAWNPUNCTIREIR
Cathepsin B [Homo sapiens]  DQGSOGSCWAFGAVEAISDRCIHTNAHVSEVEVESDA0D4VSAEDLLTO0GSMOGDGC
Cathepsin B [Xenopus laevis]  DQGSO8SCWAFGAVEAISDRCVHTNGKVEVSAEDLLSOOGDE0GMC
Cathepsin B [Homo sapiens]  NGYPAEANFWTRKGLVSGGLYESHVGCRPYSIPCEHHVNGSRPCTG
Cathepsin B [Xenopus laevis]  NGYPSGWQFWTETGLVSGGLYESHVGCRPYSIPCEHHBNGSREPCKG
Cathepsin B [Homo sapiens]  E-GDTPKCSKICEPYSPTYQDKHYGNSY5SVSNSEKDIAMEIYKNGPV
Cathepsin B [Xenopus laevis]  EEGDTFKCVQCEEYGSPAYTDKHFGETTSYGVPTSEKIMEAIYKNGPV
Cathepsin B [Homo sapiens]  EGA8SV3DFLYKSGVY4HVTGEMMGHA1RLGGGVEHNGTPYLVANS
Cathepsin B [Xenopus laevis]  EGAFLVYADVFLYKSGVY4HETGEELGGHA1KILG0GVEHNGTPYWLANS
Cathepsin B [Homo sapiens]  WNTDGNFKILRGQDHOIESEVAVIPRTDQYWPK
Cathepsin B [Xenopus laevis]  WNTDGNFKILRGKHOGIESEVAVIPRTDQYWPK

B

GQYFSYPVSVNVNSDKLLYPAVTVCCTLNPYQAIIQANDLDKLDLATHTL1TLTYGNYTSEEHGRHTTNRRREAAPLPHPLEITEGIDEILHHRASLDKNESSEMVEKRD
WNFGFKLDN0TGGDCYYKTYSSGVAIREWYRFQYVINLARPNIKDNITQNEGLELF
IFSCRFNDEPC1TDGNYSFHPHYGCNCTFNNHRQSEGIFWNSMPGMKNGSLLRL
IEQHDYPLLLSTVAGARVLVGLNSNEPAFMDEGGFNI0PGVETSIGMRKEISRLGDY
SDCTEDGSDLDVTNLFNSEYTDQCVRSC0QAIMVERCGCAYAFLPDGAEYCDY
DKQKSW0HCYYKLKEFSSDLGCTKCRKPCQLTYRNLASYRWPCTVŞENWVV
LQTLSSSNAKRDGAALKNIY6ME6Y6SESATINMVMILSLMSGQWSLWFGS
Fig. 6

A. Transepithelial Current (µA/cm²) vs. Time (minutes) with Cathepsin B inhibitor (10 µM).

B. Bar graph comparing Current (µA/cm²) between CTRL and Cathepsin B siRNA groups.

C. Western blot (WB) showing anti-cathepsin B antibody at 50 kDa.
Cathepsin B inhibitor

MOCK

75 kDa

Cell Surface Biotinylation

WB: ENaC alpha

Fig. 7

Relative Change in Alpha ENaC (Cathepsin B inhibitor/mock)

(D)

(Vehicle) Cathepsin B Inhibitor

(N(Number of Channels)

1 2 3 4

Whole cell lysate membrane

* *
Fig. 8

secreted
Cat B
ENaC α β γ
extracellular space
apical membrane
cytoplasm
clostrhin coated pit
golgi
recycling
endosome
lysosome
ubiquitination/degradation

ER
Cat B
furin
Cat B
Cat B
Cat B
Cathepsin B is secreted apically from Xenopus 2F3 cells and cleaves the epithelial sodium channel (ENaC) to increase its activity
Abdel A. Alli, John Z. Song, Otor Al-Khalili, Hui-Fang Bao, He-Ping Ma, Alia A. Alli and Douglas C. Eaton

J. Biol. Chem. published online July 10, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M111.338574

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts